NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $70.83
  • Forecasted Upside: 49.79 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.66 (3.64%)

This chart shows the closing price for ARWR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arrowhead Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARWR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARWR

Analyst Price Target is $70.83
▲ +49.79% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $70.83, with a high forecast of $110.00 and a low forecast of $36.00. The average price target represents a 49.79% upside from the last price of $47.29.

This chart shows the closing price for ARWR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Arrowhead Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022The Goldman Sachs GroupBoost Price TargetBuy$58.00 ➝ $65.00Low
8/5/2022Chardan CapitalBoost Price Target$80.00 ➝ $82.00Low
7/14/2022HC WainwrightReiterated RatingBuy$110.00Low
6/3/2022HC WainwrightBoost Price TargetBuy$100.00 ➝ $110.00High
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$90.00 ➝ $66.00High
5/11/2022Piper SandlerLower Price Target$89.00 ➝ $72.00High
5/11/2022Robert W. BairdUpgradeNeutral ➝ Outperform$71.00 ➝ $60.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/23/2022HC WainwrightReiterated RatingBuy$100.00High
2/8/2022HC WainwrightReiterated RatingBuy$100.00Low
2/3/2022SVB LeerinkLower Price TargetMarket Perform$46.00 ➝ $36.00Low
1/28/2022SVB LeerinkBoost Price TargetMarket Perform$45.00 ➝ $46.00High
1/19/2022The Goldman Sachs GroupUpgradeNeutral ➝ BuyHigh
11/23/2021SVB LeerinkBoost Price TargetMarket Perform$44.00 ➝ $45.00Low
8/10/2021HC WainwrightBoost Price TargetBuy$95.00 ➝ $100.00Medium
8/6/2021Chardan CapitalLower Price TargetBuy$97.00 ➝ $94.00High
7/2/2021HC WainwrightReiterated RatingBuy$95.00N/A
7/2/2021Piper SandlerLower Price TargetOverweight$109.00 ➝ $89.00High
6/27/2021SVB LeerinkReiterated RatingHoldHigh
6/21/2021Piper SandlerBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $109.00Low
2/8/2021CitigroupBoost Price Target$90.00 ➝ $110.00Medium
2/8/2021B. RileyBoost Price TargetBuy$98.00 ➝ $106.00High
2/5/2021Piper SandlerBoost Price TargetOverweight$90.00 ➝ $99.00High
2/5/2021Chardan CapitalBoost Price TargetBuy$81.00 ➝ $97.00High
2/5/2021HC WainwrightBoost Price TargetBuy$90.00 ➝ $95.00High
12/21/2020Robert W. BairdDowngradeOutperform ➝ Neutral$75.00High
12/15/2020UBS GroupInitiated CoverageBuy$95.00Low
11/24/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$62.00 ➝ $80.00High
11/24/2020Cantor FitzgeraldBoost Price TargetOverweight$58.00 ➝ $80.00High
11/24/2020SVB LeerinkLower Price TargetMarket Perform$35.00 ➝ $34.00High
11/19/2020Smith Barney CitigroupInitiated CoverageBuy$90.00Low
11/17/2020B. RileyBoost Price TargetBuy ➝ Positive$68.00 ➝ $98.00Low
11/16/2020Robert W. BairdBoost Price TargetOutperform$70.00 ➝ $75.00Low
10/12/2020B. RileyBoost Price Target$57.00 ➝ $68.00Low
10/12/2020HC WainwrightReiterated RatingBuyLow
10/8/2020Piper SandlerBoost Price Target$80.00 ➝ $90.00High
9/17/2020SVB LeerinkBoost Price TargetMarket Perform$29.00 ➝ $31.00Low
8/24/2020HC WainwrightReiterated RatingBuyLow
7/29/2020Chardan CapitalReiterated RatingBuy$81.00High
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$62.00High
5/10/2020B. RileyReiterated RatingBuy$57.00High
5/8/2020Cantor FitzgeraldReiterated RatingBuy$60.00 ➝ $58.00High
5/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$58.00High
4/15/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$55.00 ➝ $60.00High
3/31/2020B. RileyReiterated RatingBuy$57.00High
3/24/2020SVB LeerinkUpgradeUnderperform ➝ Market Perform$29.00Medium
3/17/2020The Goldman Sachs GroupInitiated CoverageNeutral$45.00Medium
3/13/2020B. RileyLower Price TargetBuy$83.00 ➝ $57.00High
2/7/2020Jefferies Financial GroupBoost Price Target$77.00 ➝ $80.00Medium
2/6/2020B. RileyReiterated RatingBuy$83.00High
2/6/2020Cantor FitzgeraldBoost Price TargetNeutral$50.00 ➝ $55.00High
1/24/2020B. RileyReiterated RatingBuy$83.00Low
1/21/2020SVB LeerinkInitiated CoverageUnderperform$32.00High
12/12/2019OppenheimerInitiated CoverageHoldMedium
12/9/2019Piper Jaffray CompaniesBoost Price TargetOverweight$72.00 ➝ $80.00Medium
11/29/2019Chardan CapitalReiterated RatingBuy$45.00 ➝ $81.00Medium
11/27/2019B. RileyReiterated RatingBuy$59.00 ➝ $83.00High
11/26/2019S&P Equity ResearchReiterated RatingBuyMedium
11/26/2019Piper Jaffray CompaniesReiterated RatingOverweight$54.00 ➝ $72.00High
11/25/2019Robert W. BairdUpgradeNeutral ➝ Outperform$39.00 ➝ $70.00High
11/19/2019Cantor FitzgeraldReiterated RatingNeutral$24.00 ➝ $50.00Medium
11/13/2019B. RileyBoost Price TargetBuy$46.00 ➝ $59.00Low
10/24/2019Robert W. BairdDowngradeOutperform ➝ Neutral$39.00High
10/22/2019Chardan CapitalBoost Price TargetBuy$32.00 ➝ $45.00High
10/21/2019B. RileySet Price TargetBuy$46.00High
10/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$50.00 ➝ $54.00Low
10/17/2019Cantor FitzgeraldReiterated RatingNeutralLow
10/2/2019Robert W. BairdInitiated CoverageOutperform$39.00Medium
9/16/2019Piper Jaffray CompaniesReiterated RatingOverweight$50.00Medium
8/19/2019B. RileyBoost Price TargetBuy$32.00 ➝ $46.00High
8/6/2019Piper Jaffray CompaniesBoost Price TargetOverweight$33.00 ➝ $50.00Low
6/27/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$24.00High
5/28/2019B. RileyBoost Price TargetBuy$26.00 ➝ $32.00Low
5/13/2019B. RileyBoost Price TargetBuy$19.00 ➝ $26.00High
4/16/2019Piper Jaffray CompaniesBoost Price TargetOverweight$25.00 ➝ $33.00Medium
4/12/2019Cantor FitzgeraldSet Price TargetBuy$24.00Low
2/11/2019Chardan CapitalReiterated RatingBuy$24.50High
12/17/2018Chardan CapitalReiterated RatingBuy$24.50Low
12/11/2018Cantor FitzgeraldSet Price TargetBuy$24.00High
10/17/2018William BlairReiterated RatingOutperformMedium
10/14/2018Chardan CapitalSet Price TargetBuy$25.00Low
10/11/2018Cantor FitzgeraldReiterated RatingBuy$24.00Low
10/4/2018Cantor FitzgeraldBoost Price TargetOverweight$18.00 ➝ $24.00High
10/4/2018Piper Jaffray CompaniesReiterated RatingOverweight$25.00High
10/2/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
9/14/2018Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$24.00Medium
9/6/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$17.50 ➝ $24.50Medium
9/6/2018B. RileyUpgradeNeutral ➝ Buy$18.00 ➝ $19.00High
9/6/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
8/13/2018Chardan CapitalReiterated RatingBuy$17.50Medium
8/8/2018Cantor FitzgeraldReiterated RatingOverweight$13.00Medium
8/8/2018Jefferies Financial GroupReiterated RatingBuy$20.00Low
8/8/2018B. RileyBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $18.00High
8/7/2018Cantor FitzgeraldSet Price TargetBuy$13.00 ➝ $18.00High
8/1/2018Cantor FitzgeraldInitiated CoverageBuy$13.00Low
7/8/2018Chardan CapitalSet Price TargetBuy$16.00High
7/2/2018Chardan CapitalBoost Price TargetBuy$9.50 ➝ $16.00High
6/29/2018Piper Jaffray CompaniesReiterated RatingOverweight$17.00Low
6/18/2018S&P Equity ResearchLower Price Target$13.76 ➝ $11.68Medium
6/18/2018Cantor FitzgeraldReiterated RatingBuy$13.00High
5/30/2018Cantor FitzgeraldReiterated RatingBuy$13.00High
5/8/2018Piper Jaffray CompaniesBoost Price TargetOverweight$11.00High
5/8/2018Cantor FitzgeraldUpgradeNeutral ➝ Overweight$13.00High
3/27/2018Jefferies Financial GroupInitiated CoverageBuy$10.00High
2/19/2018Chardan CapitalReiterated RatingBuy$7.00Low
2/12/2018B. RileyBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00Medium
2/12/2018Cantor FitzgeraldSet Price TargetNeutral ➝ Neutral$2.00 ➝ $5.00Medium
1/16/2018Chardan CapitalReiterated RatingNeutralMedium
1/5/2018B. RileyInitiated CoverageNeutral ➝ Neutral$3.00Medium
12/12/2017Cantor FitzgeraldSet Price TargetHold$2.00Medium
11/27/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$5.50High
9/25/2017Cantor FitzgeraldReiterated RatingHold$2.00Medium
9/18/2017William BlairUpgradeMarket Perform ➝ OutperformHigh
9/15/2017Cantor FitzgeraldReiterated RatingHold$1.00 ➝ $2.00High
9/13/2017Chardan CapitalReiterated RatingNeutralMedium
(Data available from 8/12/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $47.29
Low: $46.06
High: $47.90

50 Day Range

MA: $38.33
Low: $27.79
High: $47.02

52 Week Range

Now: $47.29
Low: $26.81
High: $84.83


603,747 shs

Average Volume

789,706 shs

Market Capitalization

$5.01 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?

The following equities research analysts have issued research reports on Arrowhead Pharmaceuticals in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Piper Sandler, Robert W. Baird,, SVB Leerink LLC, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for ARWR.

What is the current price target for Arrowhead Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Arrowhead Pharmaceuticals in the last year. Their average twelve-month price target is $70.83, suggesting a possible upside of 51.4%. HC Wainwright has the highest price target set, predicting ARWR will reach $110.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $36.00 for Arrowhead Pharmaceuticals in the next year.
View the latest price targets for ARWR.

What is the current consensus analyst rating for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARWR will outperform the market and that investors should add to their positions of Arrowhead Pharmaceuticals.
View the latest ratings for ARWR.

What other companies compete with Arrowhead Pharmaceuticals?

How do I contact Arrowhead Pharmaceuticals' investor relations team?

Arrowhead Pharmaceuticals' physical mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company's listed phone number is (626) 304-3400 and its investor relations email address is [email protected] The official website for Arrowhead Pharmaceuticals is Learn More about contacing Arrowhead Pharmaceuticals investor relations.